Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,000 and keeps a Buy rating ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Here are 11 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 3: ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

President-elect Donald Trump 's threat to "tariff Denmark at a very high level" if it refuses to give up Greenland could ...

By Shashwat Chauhan and Nikhil Sharma (Reuters) -European shares edged lower on Friday as elevated government bond yields ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.